GUINEA PIG BLOOD: A MODEL FOR THE PHARMACOLOGIC MODULATION OF THE GPIb/IX-VWF AXIS

Abstract Antithrombotic activity of two recombinant GPIb-binding fragments of vWF, RG12986 (residues 445-733), and VCL (residues 504-728), were assessed in an ex vivo capillary perfusion chamber exposing human type III collagen to native nonanticoagulated guinea pig blood. Platelet adhesion and thrombus formation were evaluated by computer assisted morphometry for two shear rates (650 and 1800 s −1 ) and for two perfusion times (1.5 and 4 min). At 1800 s −1 and 4 min of perfusion, platelet adhesion decreased from 63 ± 7% for control, to 46 ± 4% for 20 mg/kg RG12986, and to 29 ± 5% for 4 mg/kg VCL, and the mean thrombus height dropped from 40 ± 8 μm to 24 ± 3 μm and 7.5 ± 1 μm, respectively. The two doses did not change bleeding time values. Our results suggest that guinea pig blood and the circular perfusion chamber represent a good model for the evaluation of limited amount of GPIb/IX-vWF axis inhibitors.